Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (4938)	5/18/1998 2:01:00 PM
From: Andreas Helke	Respond to of 9719

The cancer biotechs in my portfolio are acting pretty funny too. Ligand and Agouron where I have big positions are largely ignoring news and media coverage. Sugen went from being up big do being down big. So far I have not figured out why and if it is a buying opportunity. Sugen was on the top of my buy list before EntreMeds drugs on the New York Times front page screwed up my biotech buying plans. I did not get more shares before due to the lack of funds. EntreMed got the expected pop thanks to the news that preliminary human trials will begin before EntreMed even files its IND for angiostatin and endostatin. Corixa where I did not expect anything today turned out to be the big winner thanks to a well timed press release. Corixa is a vaccine development company that today announced that its cancer vaccine against Her2/neu did provide an immune response in the majority of patients in its phase I trial. Corixa was slowly and steadily going down to $6 from its $14 IPO last year. Today its oscillating between $8 and $10. Andreas